Treatment with ZYKADIA may cause GI Adverse Reactions, Hepatic and Embryo-fetal Toxicities, Interstitial Lung Disease/Pneumonitis, QTc Interval Prolongation, Hyperglycemia, Bradycardia, Pancreatiti...
FROM FINANCIAL ASSISTANCE TO ONLINE SUPPORT, NOVARTIS ONCOLOGY HAS RESOURCES TO HELP YOUR ELIGIBLE PATIENTS DURING THEIR TREATMENT JOURNEY
Novartis Oncology shares your commitment to helping eligible patients receive the medicines prescribed. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.
You can get more information about PANO by calling 1-800-282-7630 or visiting www.HCP.Novartis.com/Access.
Materials to assist with patient access are available at www.ZYKADIA.com.
FREE TRIAL PROGRAM HELPS ELIGIBLE PATIENTS START THERAPY QUICKLY
The ZYKADIA® (ceritinib) 14-Day Free Trial helps eligible patients start therapy quickly. A 14-day supply is shipped directly to a patient's home or another convenient location.
This one-time trial is available to all patients prescribed ZYKADIA for a US Food and Drug Administration (FDA)-approved indication without regard to purchase of ZYKADIA or any other product.
To find the Novartis Oncology Service Request Form, visit www.HCP.Novartis.com/Access.
NOVARTIS ONCOLOGY UNIVERSAL CO-PAY PROGRAM
At Novartis Oncology, we've made it easier for patients to access co-pay assistance on their prescription costs for almost all Novartis Oncology products. Patients may be eligible for immediate co-pay savings on their next prescription.
Limitations apply. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
ZYKADIA® (ceritinib) capsules is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
IMPORTANT SAFETY INFORMATION for ZYKADIA® (ceritinib) capsules
Gastrointestinal Adverse Reactions
Interstitial Lung Disease/Pneumonitis
QTc Interval Prolongation
Effect of Other Drugs on Ceritinib
Effect of Ceritinib on Other Drugs